SCHEMBL19385241

SCHEMBL19385241

c1ccc(-c2ccc3nc(C4CCCN4)[nH]c3c2)cc1

nearest known ligand 0.62

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ SCN10A Q9Y5Y9 1/20 0.62
▸ USP30 Q70CQ3 4/20 0.55
▸ NPY5R Q15761 3/20 0.50
▸ AAK1 Q2M2I8 2/20 0.45
▸ PARP1 P09874 5/20 0.44
▸ ROCK2 O75116 1/20 0.42
▸ HTR2B P41595 1/20 0.42
▸ TAAR1 Q96RJ0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19385240 1.00 SCN10A (0.62) SCN10AUSP30NPY5RAAK1PARP1
SCHEMBL12053448 0.95 SCN10A (0.67) SCN10AUSP30NPY5RAAK1PARP1
Trifluoroacetic Acid SCHEMBL29562481 0.90 SCN10A (0.55) SCN10AUSP30NPY5RPARP1HTR2B
SCHEMBL16907913 0.89 SCN10A (0.64) SCN10AUSP30NPY5RAAK1PARP1
SCHEMBL1293368 0.89 SCN10A (0.64) SCN10AUSP30NPY5RAAK1PARP1
SCHEMBL1293364 0.89 SCN10A (0.64) SCN10AUSP30NPY5RAAK1PARP1
SCHEMBL1519099 0.88 SCN10A (0.60) SCN10AUSP30NPY5RAAK1PARP1
SCHEMBL1519551 0.88 SCN10A (0.60) SCN10AUSP30NPY5RAAK1PARP1
SCHEMBL12798837 0.88 SCN10A (0.63) SCN10AUSP30NPY5RAAK1PARP1
SCHEMBL1293406 0.88 SCN10A (0.63) SCN10AUSP30NPY5RAAK1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11945797-B2 1-cyano-pyrrolidine derivatives as dub inhibitors MISSION THERAPEUTICS LIMITED (GB) 2024-04-02 — — US disclosed
US-20220177451-A1 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2022-06-09 — — US disclosed
US-11352339-B2 1-cyano-pyrrolidine derivatives as DUB inhibitors MISSION THERAPEUTICS LIMITED (GB) 2022-06-07 — — US disclosed
EP-3433246-B1 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS MISSION THERAPEUTICS LTD (GB) 2022-05-04 — — EP disclosed
CN-108884068-B 1-cyano-pyrrolidine derivatives as DUB inhibitors 特殊治疗有限公司 2021-02-26 — — CN disclosed
US-20200331888-A1 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2020-10-22 — — US disclosed
EP-3433246-A1 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS Mission Therapeutics Limited (GB) 2019-01-30 — — EP disclosed
WO-2017163078-A1 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2017-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352339-B2 1-cyano-pyrrolidine derivatives as DUB inhibitors USP30, USP28, USP1 SCN10A 3320/4885USP30 1/4885NPY5R 1555/4885
US-20220177451-A1 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS USP30, USP28, USP1 SCN10A 3320/4885USP30 1/4885NPY5R 1555/4885
US-11945797-B2 1-cyano-pyrrolidine derivatives as dub inhibitors USP30, USP28, USP1 SCN10A 3320/4885USP30 1/4885NPY5R 1555/4885
US-20200331888-A1 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS USP30, USP28, USP1 SCN10A 3320/4885USP30 1/4885NPY5R 1555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback